BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Gt Healthcare Capital Partners

BioCentury | Apr 29, 2021
Product Development

April 28 Quick Takes: Brukinsa data buoy BeiGene; plus Adverum, Dynamk, Pfizer-Amplyx, Boundless Bio and Clarus   

Positive Phase III data for Brukinsa zanubrutinib lifted shares of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) 9% on NASDAQ, leaving the company with a market cap of $32 billion. The Btk inhibitor showed
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

Boundless Bio launches with $46M series A to tackle unexplored extrachromosomal DNA target space in cancer
BioCentury | Jan 11, 2019
Finance

Exscientia looks inward

How Exscientia plans to use $26M B round to build out AI-driven pipeline
BioCentury | Dec 14, 2016
Financial News

Oxford Nanopore completes venture financing

BioCentury | Dec 13, 2016
Financial News

Oxford Nanopore raises L100M in private placement

Items per page:
1 - 6 of 6